From polyaphron technology to fixed combinations, new formulations improve tolerability, adherence, and patient satisfaction. Join Drs Feldman and Armstrong as they discuss. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/ca8/p04/podcast-psoriasis-s3-ep6-2026a100069z. The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Psoriasis https://emedicine.medscape.com/article/1943419-overview expertscape https://expertscape.com/ PDE4 Inhibitors: Bridging Molecular Insights With Clinical Impact https://pubmed.ncbi.nlm.nih.gov/40465498/ Topical Corticosteroids https://www.ncbi.nlm.nih.gov/books/NBK532940/ Psoriasis Clinical Guideline https://www.aad.org/member/clinical-quality/guidelines/psoriasis Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): The Correlation Between Disease Severity and Psychological Burden in Patients Treated With Biological Therapies https://pubmed.ncbi.nlm.nih.gov/23425140/ Keratosis Pilaris https://emedicine.medscape.com/article/1070651-overview Review of the Mechanism of Action of Coal Tar in Psoriasis https://pubmed.ncbi.nlm.nih.gov/28814117/ Treatment Adherence Intervention Studies in Dermatology and Guidance on How to Support Adherence https://pubmed.ncbi.nlm.nih.gov/28188596/ Polyaphron Dispersion Technology, a Novel Topical Formulation and Delivery System Combining Drug Penetration, Local Tolerability and Convenience of Application https://pubmed.ncbi.nlm.nih.gov/36050567/ Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits https://pubmed.ncbi.nlm.nih.gov/34106439/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.